Literature DB >> 8901475

Salvage of jeopardized myocardium by ischemic preconditioning: is the quest over?

R Strasser1, P Htun, W Schaper.   

Abstract

Helmholtz is quoted to have said that if he'd had any influence in creation he would have returned the human eye to its maker for revisions. The same could be said of the heart with its only very rudimentary ability to defend itself against ischemia. Ischemia was obviously not a problem during evolution: Early man did not live much longer than prime time for reproduction and no selection bias existed to prevent vascular diseases, an affliction of later life. In spite of this natural disadvantage of aged males the number of existing although not very efficient defense mechanisms is surprisingly large. It is the general belief that the knowledge of these mechanisms may lead to the development of new therapies that hopefully improve the imperfect product of natural selection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8901475     DOI: 10.1007/bf00240051

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  24 in total

1.  Coupling of ATP-sensitive K+ channels to A1 receptors by G proteins in rat ventricular myocytes.

Authors:  G E Kirsch; J Codina; L Birnbaumer; A M Brown
Journal:  Am J Physiol       Date:  1990-09

2.  Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features.

Authors:  E Deutsch; M Berger; W G Kussmaul; J W Hirshfeld; H C Herrmann; W K Laskey
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

3.  Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.

Authors:  G I Barbash; H D White; M Modan; F Van de Werf
Journal:  J Am Coll Cardiol       Date:  1992-07       Impact factor: 24.094

4.  Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning?

Authors:  R A Kloner; T Shook; K Przyklenk; V G Davis; L Junio; R V Matthews; S Burstein; M Gibson; W K Poole; C P Cannon
Journal:  Circulation       Date:  1995-01-01       Impact factor: 29.690

5.  The effects of global ischemia and reperfusion on human myocardium: quantitative evaluation by electron microscopic morphometry.

Authors:  J Schaper; F Schwarz; H Kittstein; G Stämmler; B Winkler; H Scheld; F Hehrlein
Journal:  Ann Thorac Surg       Date:  1982-02       Impact factor: 4.330

6.  Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction.

Authors:  M S Marber; D S Latchman; J M Walker; D M Yellon
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

7.  Influence of collateral blood flow and of variations in MVO2 on tissue-ATP content in ischemic and infarcted myocardium.

Authors:  W Schaper; K Binz; S Sass; B Winkler
Journal:  J Mol Cell Cardiol       Date:  1987-01       Impact factor: 5.000

8.  Neutral endopeptidase in the heart. Neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation.

Authors:  G Piedimonte; J A Nadel; C S Long; J I Hoffman
Journal:  Circ Res       Date:  1994-10       Impact factor: 17.367

9.  Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors.

Authors:  G J Grover; P G Sleph; S Dzwonczyk
Journal:  Circulation       Date:  1992-10       Impact factor: 29.690

10.  Myocardial protection with preconditioning.

Authors:  G C Li; J A Vasquez; K P Gallagher; B R Lucchesi
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

View more
  1 in total

Review 1.  The injured nervous system: a Darwinian perspective.

Authors:  Zachary M Weil; Greg J Norman; A Courtney DeVries; Randy J Nelson
Journal:  Prog Neurobiol       Date:  2008-06-14       Impact factor: 11.685

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.